Avacta Group PLC Director/PDMR Shareholding (4617M)

TIDMAVCT

RNS Number : 4617M

Avacta Group PLC

28 July 2017

28 July 2017

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Director/PDMR Shareholding

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, announces that its Chief Executive Officer, Dr Alastair Smith has today transferred 87,850 ordinary shares of 10p each ("Ordinary Shares") from his personal holding to his self-invested personal pension (SIPP) at a price of 83.0p per Ordinary Share. Following this transaction, Dr Smith's total interest in Ordinary Shares has remained unchanged.

Enquiries:

 
     Avacta Group plc                              Tel: +44 (0) 
      Alastair Smith, Chief Executive               844 414 0452 
      Officer                                       www.avacta.com 
      Tony Gardiner, Chief Financial 
      Officer 
     finnCap Ltd                                   Tel: +44 (0) 
      Geoff Nash / Giles Rolls - Nominated          207 220 0500 
      Adviser                                       www.finncap.com 
      Tim Redfern / Alice Lane - Corporate 
      Broking 
                                                    Tel: +44 (0) 
      WG Partners                                   203 705 9318 
      David Wilson                                  Tel: +44 (0) 
      Nigel Barnes                                  203 705 9217 
      Claes Spang                                   www.wgpartners.co.uk 
     Media Enquiries                               Tel: +44 (0) 
      FTI Consulting                                203 727 1000 
      Simon Conway / Natalie Garland-Collins        [e-mail] 
 

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
     1.       Details of the person discharging managerial 
               responsibilities / person closely associated 
-------  ------------------------------------------------------------------------------------------------------------ 
     a)       Name                                 Alastair Smith 
-------  -----------------------------------  ----------------------------------------------------------------------- 
     2.       Reason for the Notification 
-------  ------------------------------------------------------------------------------------------------------------ 
     a)       Position/status                      Chief Executive Officer 
-------  -----------------------------------  ----------------------------------------------------------------------- 
     b)       Initial notification/Amendment            Initial notification 
-------  -----------------------------------  ----------------------------------------------------------------------- 
 3.           Details of the issuer, emission allowance 
               market participant, auction platform, auctioneer 
               or auction monitor 
-------  ------------------------------------------------------------------------------------------------------------ 
     a)       Name                                 Avacta Group Plc 
-------  -----------------------------------  ----------------------------------------------------------------------- 
     b)       LEI                                  n/a 
-------  -----------------------------------  ----------------------------------------------------------------------- 
 4.           Details of the transaction(s): section to 
               be repeated for (i) each type of instrument; 
               (ii) each type of transaction; (iii) each 
               date; and (iv) each place where transactions 
               have been conducted 
-------  ------------------------------------------------------------------------------------------------------------ 
     a)       Description of                             Ordinary shares 
               the Financial                               of 10p 
               instrument, type 
               of instrument 
------- 
              Identification                       GB00BYYW9G87 
               code 
-------  -----------------------------------  ----------------------------------------------------------------------- 
     b)       Nature of the                              Transfer of ordinary shares to SIPP via a sale and purchase. 
               transaction 
-------  -----------------------------------  ----------------------------------------------------------------------- 
     c)       Price(s) and                              Price(s)          Volume(s) 
               volume(s)                            ----------------  -------------- 
                                                         83.0 pence        87,850 
                                                    ----------------  -------------- 
-------  -----------------------------------  ----------------------------------------------------------------------- 
     d)       Aggregated information: 
                *    Aggregated volume               See above 
 
 
                *    Price 
-------  -----------------------------------  ----------------------------------------------------------------------- 
     e)       Date of the transaction              28 July 2017 
-------  -----------------------------------  ----------------------------------------------------------------------- 
     f)       Place of the                         London Stock Exchange, AIM 
               transaction                          Market (XLON) 
-------  -----------------------------------  ----------------------------------------------------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHOKFDDBBKDQOB

(END) Dow Jones Newswires

July 28, 2017 08:15 ET (12:15 GMT)